Vig­il Neu­ro­science hits Wall Street with two ex-Am­gen TREM2 ag­o­nists

Big Phar­ma large­ly aban­doned neu­ro­science over the last sev­er­al years — but the folks at Vig­il Neu­ro­science be­lieve a re­nais­sance is around the cor­ner, and ap­par­ent­ly, so do in­vestors.

The Cam­bridge, MA-based start­up closed a $98 mil­lion IPO on Tues­day, pric­ing 7 mil­lion shares at $14, just be­low an ex­pect­ed $15 to $17 range. Most of that is go­ing to­ward VGL101, an ex-Am­gen TREM2 ag­o­nist in Phase I for a rare neu­rode­gen­er­a­tive dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER